Zymeworks Inc. (ZYME) stock plunged 5.46% in the after-hours trading session on Wednesday after reporting a wider-than-expected loss and lower-than-anticipated revenue for the fourth quarter.
The biopharmaceutical company reported a net loss of $0.31 per diluted share for the quarter, significantly missing analysts' expectations of a $0.03 loss. The company's revenue also fell short, coming in at $31 million compared to the estimated $45.2 million.
The disappointing results likely contributed to the sharp decline in Zymeworks' stock price in the after-hours market, as investors reacted negatively to the company's performance. The broader market outlook and future growth prospects may also have played a role in the sell-off.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.